



Arming the patient's immune system to fight cancer

---

# NLS Days 2016

CEO, Gunnar Gårdemyr

# What is immune oncology?

- The role of the immune system is to defend the body against threats eg bacteria, cancer
- Constant “power struggle” between the immune system and cancer
- If the immune system “looses” we get ill
- Immune oncology is about helping the immune system to beat cancer

Targovax has 2 platforms in development  
aiming to help the immune system to beat cancer



# Immunotherapy – The Future of Cancer Treatment



Prior to treatment



4 weeks



8 weeks



20 weeks



8 months



1 year

All pictures are an example of Yervoy (BMS) treated melanoma

# Targovax at a glance


1	Arming the patient's immune system to fight cancer	<ul style="list-style-type: none"><li>✓ Oncolytic adenoviruses targeting all solid, injectable tumors</li><li>✓ Peptides targeting all RAS-mutated cancers</li><li>✓ 2 clinical trial collaborations signed 2015</li></ul>
2	Unique technologies with promising data	<ul style="list-style-type: none"><li>✓ Promising phase I data in 2 platforms</li><li>✓ 3 orphan indications</li><li>✓ Safety data in more than 200 patients</li></ul>
3	Multiple value inflection points	<ul style="list-style-type: none"><li>✓ 6 phase I/II combination trials,</li><li>✓ All 6 trials have readouts in 2017</li></ul>
4	Experienced management team	<ul style="list-style-type: none"><li>✓ Strong Board and Management with international pharmaceutical drug development and commercial experience</li></ul>
5	Corporate	<ul style="list-style-type: none"><li>✓ Strong shareholder base including specialist investor HealthCap</li><li>✓ IPO in July 2016 (OSE:TRVX)</li><li>✓ Cash approx. NOK 200m</li></ul>

# Differentiated assets with 3 orphan indications

	Cancer indication(s)	Program	Discovery	Pre-clinical	Phase I	Phase II	Phase III
Development	Resected pancreatic	TG01	[Progress bar spanning Discovery, Pre-clinical, and Phase I]				
	Mesothelioma	ONCOS-102	[Progress bar spanning Discovery and Pre-clinical]				
	Melanoma	ONCOS-102	[Progress bar spanning Discovery and Pre-clinical]				
	Colorectal	TG02	[Progress bar spanning Discovery and Pre-clinical]				
Exploratory	Ovarian	ONCOS-102	[Progress bar spanning Discovery and Pre-clinical]				
	Prostate	ONCOS-102	[Progress bar spanning Discovery and Pre-clinical]				
Discovery	<i>Discovery</i>	TG03	[Progress bar in Discovery]				
		ONCOS-402	[Progress bar in Discovery]				
		ONCOS-802	[Progress bar in Discovery]				
		ONCOS-902	[Progress bar in Discovery]				

- A broad and diversified pipeline in multiple indications
- Low price tag on go/no-go decisions
- Orphan indications: resected pancreatic, mesothelioma and ovarian cancer

# Clinical development program: 6 separate shots on goal



# Unique immuno-oncology portfolio with promising data

- 1 Immuno-oncology is the fastest growing life science segment
- 2 Unique portfolio with promising phase I data
- 3 Multiple value inflection points
- 4 Experienced management team
- 5 Backed by leading life science investors

